Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Leukemia
Tamibarotene used to treat relapsed or refractory acute promyelocytic leukemia
December 29th, 2005
Tamibarotene could be used to treat relapsed or refractory acute promyelocytic leukemia (APL). "APL is a form of acute myeloid leukemia (AML) caused by a specific chromosomal translocation: t(15;17). This translocation creates a fusion between the promyelocytic (PML) leukemia gene and the retinoic acid receptor alpha (RAR alpha) gene to arrest the maturation of myeloid cells at the promyelocytic stage, leading to increased proliferation of promyelocytes," scientists reported in the journal Drugs of the Future. "These accumulate in the bone marrow and peripheral blood, replacing normal blood cells. All-trans-retinoic acid (ATRA) therapy targets...
Source: Blood Weekly (2005-12-29)
|
